Mr. Andrew Ng
- Head of Healthcare, Private Equity, VMS Group
Andrew Ng is a Managing Director and Head of Healthcare of VMS Group and an Investment Partner of Panacea Venture. He has over 13 years of experience in the healthcare industry across Asia and the US. Andrew has established the healthcare practice of VMS Group in 2017 and led multiple growth-stage investments for VMS across the therapeutics, diagnostics, medical device and CRO/CDMO verticals. He has also served as an Investment Partner of Panacea Venture, a global healthcare venture capital firm, since 2021.
Prior to that, Andrew was responsible for the China Healthcare Equity Research at Barclays Capital based in Hong Kong. Before that, he was an investment banker covering healthcare clients across the Asia Pacific region at Barclays Capital with a focus in healthcare cross-border M&A. Andrew started his career as a management consultant at ZS Associate in the United States advising global pharma on sales & marketing strategy and operations.
Andrew has been on the board of multiple companies that carry out product development, manufacturing and sales in the biotechnology, medical equipment and CXO industries. These companies include New Horizon Health, Chime Biologics, Jade Biomedical, SyMap Medical, Yizun Biomedicine and Profusa.
Andrew received an MBA from INSEAD, a M.Eng. degree and a BS degree in Operations Research & Engineering from Cornell University.